Steady Climb for Johnson & Johnson Stock Amid Regulatory Challenges and Robust Growth Prospects

# Johnson & Johnson Stock Analysis: Climbing Near 52-Week High Amid Strong Q2 Results Explore Johnson & Johnson's impressive market performance as shares reach $179.30, approaching the 52-week high of $181.16. This episode breaks down J&J's recent $2 billion U.S. manufacturing investment, strong Q2 earnings that exceeded expectations, and raised guidance for FY2025 ($10.80-$10.90 EPS). We analyze the 6% revenue growth driven by pharmaceutical and medical device divisions, increased trading volume of 9.5M shares, and analyst sentiment with Citigroup's $200 price target. Despite ongoing litigation concerns and patent challenges, discover why J&J's 62-year dividend streak and $432B market cap continue making it a healthcare sector favorite for stability-focused investors. For more http://www.quietplease.ai Stock up on these deals https://amzn.to/3QFpYIX This content was created in partnership and with the help of Artificial Intelligence AI.